Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Clinical factors associated with MBDPAll (25)MBDP (5)No MBDP (20) p Gestational age30 w (IQR 26.6 to 31.2)26.4 w (IQR 25.6-27.64)30.85 w (IQR 27.89 to 31.54) 0.021 a Birth weight1180 g (IQR 900 to 1445)900 g (IQR 765 to 950)1275 g (IQR 987.5-1568.75) 0.021 a Other comorbidities:: BPD8 (32%)5 (100%)3 (15%) 0.001 b: Pneumonia4 (16%)4 (80%)0 < 0.001 b: Hypothyroidism6 (24%)4 (80%)2 (10%) 0.005 b: Anemia10 (40%)5 (100%)5 (25%) 0.005 b: Patent ductus arteriosus9 (32%)4 (80%)5 (25%) 0.04 b: Seizures2 (8%)2 (40%)0 0.033 b First day mobilization KMC5 d (IQR 2.5 to 13.5)34 d (IQR 8 to 52)4 (IQR 2-11.2) 0.008 a Weigh gain during first month29.3 g/d (IQR 17.9 to 35.7)17.9 g/d (IQR 10.7 to 18.6)30.4 g/d (22.9 to 39.6) 0.035 a Days on exclusive PN during first month0 d (IQR 0 to 2)4 d (IQR 2 to 7)0 d (IQR 0 to 0,5) 0.001 a Days on PN during first month9 d (IQR 6 to 11)15 d (IQR 11 to 19)8 d (IQR 5 to 10) 0,007 a Days on NGT feeding42 d (IQR 21 to 71)90 d (IQR 90 to 92)27,5 d (IQR 21-57.5) 0.002 a First day fortification9 d (IQR 6 to 13)12 d (IQR 10 to 18)7 d (IQR 6 to 11) 0.028 a Nutritional intakes: Liquids (ml/kg/d)160 (IQR 149 to 168)147 (IQR 145 to 150)164.5 (IQR 157.5 to 168)0.095a: Calories (kcal/kg/d)130,8 (IQR 125.6-140.4)139.7 (IQR 122.5-139.9)130.7 (IQR 126.3-142.2)0.734a: Proteins (g/kg/d)3.7 (IQR 3.5 to 4.5)3.6 (IQR 3.6 to 4.3)3.8 (IQR 3.4 to 4.5)0.709a: Calcium (mg/kg/d)146 (IQR 134.3-183.3)146 (IQR 141.9-176.5)150.5 (IQR 134.1-185.5)0.892a: Phosphorus (mg/kg/d)83.6 (IQR 72.4-100.4)87 (IQR 76-93.8)82.3 (IQR 71.7-100.6)0.812a: Vitamin D (UI/d)600 (IQR 600 to 700)800 (IQR 500 to 835)600 (IQR 600 to 600)0.173aBPD: Bronchopulmonary dysplasia; KMC: Kangaroo mother care; PN: Parenteral Nutrition; NGT: Nasogastric Tube.
Source: Clinical factors associated with MBDP. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Role of fibroblast growth factor-23 as an early marker of metabolic bone disease of prematurity
Study design awaiting verification · BMC Pediatrics · 2024
Original publication title
Role of fibroblast growth factor-23 as an early marker of metabolic bone disease of prematurity
© The Author(s) 2024
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
Metabolic bone disease of prematurity (MBDP) remains a significant cause of morbidity in extremely premature newborns. In high-risk patients, suspected diagnosis and subsequent treatment modifications, with limitations in terms of sensitivity and specificity, rely on low phosphorus levels and/or high levels of alkaline phosphatase (ALP). We investigated the potential of fibroblast growth factor-23 (FGF23) as an early marker for MBDP when measured at 3 to 4 weeks of life in at-risk patients.
Source: PurposeAbstract: What methods does the paper describe?
A single-center prospective observational non-interventional study including preterm newborns of both sexes, with a gestational age of less than 32 weeks and/or a birth weight of less than 1500 g. In the standard biochemical screening for MBDP performed between 3 and 4 weeks of life within a nutritional profile, the determination of FGF23 was included along with other clinical and metabolic studies. The study was conducted at Marqués de Valdecilla University Hospital in Santander, Spain, from April 2020 to March 2021.
Participants provided informed consent. Biochemical analyses were conducted using various platforms, and follow-up evaluations were performed at the discretion of neonatologists. Patients at high risk for MBDP received modifications in treatment accordingly. The sample was descriptively analyzed, presenting measures of central tendency and dispersion for continuous variables, and absolute numbers/percentages for categorical ones. Tests used included t-tests, Mann: Whitney U tests, chi-square tests, logistic regressions, Pearson correlation, and ROC curve analysis (IBM SPSS Statistics version 19). Significance level: P < 0.05.
Source: MethodsAbstract: Results
In the study involving 25 at-risk premature newborns, it was found that 20% (n = 5) were diagnosed with MBDP. Three of these patients (60%) were identified as high-risk based on standard biochemical evaluation at 3 to 4 weeks of age, while the other two patients (40%) were diagnosed in subsequent weeks. However, in all 5 patients, measurement of FGF23 levels would allow for early identification and optimization of treatment before other markers become altered. Low levels of FGF23 at 3 to 4 weeks, even with normal phosphorus and ALP levels, indicate the need for modifications in nutritional supplementation.
Source: ResultsAbstract: Conclusions
MBDP remains a significant concern in extremely premature newborns. Current diagnostic methods rely on limited biochemical markers. Early detection of low FGF23 levels enables timely interventions, potentially averting demineralization.
Source: ConclusionsAuthors’ abstract
Purpose
Metabolic bone disease of prematurity (MBDP) remains a significant cause of morbidity in extremely premature newborns. In high-risk patients, suspected diagnosis and subsequent treatment modifications, with limitations in terms of sensitivity and specificity, rely on low phosphorus levels and/or high levels of alkaline phosphatase (ALP). We investigated the potential of fibroblast growth factor-23 (FGF23) as an early marker for MBDP when measured at 3 to 4 weeks of life in at-risk patients.
Methods
A single-center prospective observational non-interventional study including preterm newborns of both sexes, with a gestational age of less than 32 weeks and/or a birth weight of less than 1500 g. In the standard biochemical screening for MBDP performed between 3 and 4 weeks of life within a nutritional profile, the determination of FGF23 was included along with other clinical and metabolic studies. The study was conducted at Marqués de Valdecilla University Hospital in Santander, Spain, from April 2020 to March 2021.
Participants provided informed consent. Biochemical analyses were conducted using various platforms, and follow-up evaluations were performed at the discretion of neonatologists. Patients at high risk for MBDP received modifications in treatment accordingly. The sample was descriptively analyzed, presenting measures of central tendency and dispersion for continuous variables, and absolute numbers/percentages for categorical ones. Tests used included t-tests, Mann: Whitney U tests, chi-square tests, logistic regressions, Pearson correlation, and ROC curve analysis (IBM SPSS Statistics version 19). Significance level: P < 0.05.
Results
In the study involving 25 at-risk premature newborns, it was found that 20% (n = 5) were diagnosed with MBDP. Three of these patients (60%) were identified as high-risk based on standard biochemical evaluation at 3 to 4 weeks of age, while the other two patients (40%) were diagnosed in subsequent weeks. However, in all 5 patients, measurement of FGF23 levels would allow for early identification and optimization of treatment before other markers become altered. Low levels of FGF23 at 3 to 4 weeks, even with normal phosphorus and ALP levels, indicate the need for modifications in nutritional supplementation.
Conclusions
MBDP remains a significant concern in extremely premature newborns. Current diagnostic methods rely on limited biochemical markers. Early detection of low FGF23 levels enables timely interventions, potentially averting demineralization.
Supplementary Information
The online version contains supplementary material available at 10.1186/s12887-024-04897-7.
Key points
Question: Is fibroblast growth factor-23 (FGF23) measured at 3 to 4 weeks of life a reliable early marker for metabolic bone disease of prematurity (MBDP) in at-risk preterm newborns?
Findings:
This study was a single-center prospective observational noninterventional study conducted in a neonatal unit in Spain. The primary outcome was to investigate FGF23 as a potential early marker for MBDP. The study found that low levels of FGF23 at 3 to 4 weeks of life, even with normal phosphorus and alkaline phosphatase levels, indicated the need for modifications in nutritional supplementation. FGF23 levels at this time point were found to predict subsequent hypophosphatemic status, making it the most sensitive early marker for MBDP in at-risk preterm newborns.
Meaning: Early detection of low FGF23 levels at 3 to 4 weeks of life can help identify at-risk preterm newborns with MBDP and prompt timely treatment modifications, potentially preventing demineralization and improving outcomes in this vulnerable population.
Supplementary Information
The online version contains supplementary material available at 10.1186/s12887-024-04897-7.
Publication and source details
Original title: Role of fibroblast growth factor-23 as an early marker of metabolic bone disease of prematurity
Sandra Llorente-Pelayo; Pablo Docio; Silvia Arriola; Bernardo A. Lavín-Gómez; María T. García-Unzueta; María Ángeles Ballesteros; María J. Cabero-Pérez; Domingo González-Lamuño
BMC Pediatrics · 2024
© The Author(s) 2024https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T10:46:09.747839+00:00
DOI: 10.1186/s12887-024-04897-7 · PMC11218264